181 related articles for article (PubMed ID: 12856426)
1. [Anemia and chemotherapy of malignant hemopathies].
Damaj G; Braud AC; Hermine O
Bull Cancer; 2003 Apr; 90 Spec No():S144-51. PubMed ID: 12856426
[TBL] [Abstract][Full Text] [Related]
2. Hematopoietic growth factors in the treatment of acquired bone marrow failure states.
Marsh JC; Ganser A; Stadler M
Semin Hematol; 2007 Jul; 44(3):138-47. PubMed ID: 17631178
[TBL] [Abstract][Full Text] [Related]
3. Successful treatment of refractory anemia with a combination regimen containing recombinant human erythropoietin, low-dose methylprednisolone and nandrolone.
Tsiara SN; Chaidos A; Gouva M; Christou L; Panteli K; Kapsali E; Bourantas KL
J Exp Clin Cancer Res; 2004 Mar; 23(1):47-52. PubMed ID: 15149150
[TBL] [Abstract][Full Text] [Related]
4. Recombinant human erythropoietin therapy is very effective after an autologous peripheral blood stem cell transplant when started soon after engraftment.
Baron F; Frère P; Fillet G; Beguin Y
Clin Cancer Res; 2003 Nov; 9(15):5566-72. PubMed ID: 14654537
[TBL] [Abstract][Full Text] [Related]
5. Erythropoietin and chronic lymphocytic leukemia.
Mauro FR; Gentile M; Foa R
Rev Clin Exp Hematol; 2002; Suppl 1():21-31. PubMed ID: 12735212
[TBL] [Abstract][Full Text] [Related]
6. Low dose erythropoietin is effective in reducing transfusion requirements following allogeneic HSCT.
Fox CP; Pacey S; Das-Gupta EP; Russell NH; Byrne JL
Transfus Med; 2005 Dec; 15(6):475-80. PubMed ID: 16359418
[TBL] [Abstract][Full Text] [Related]
7. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.
Petersen SL
Dan Med Bull; 2007 May; 54(2):112-39. PubMed ID: 17521527
[TBL] [Abstract][Full Text] [Related]
8. Anemia in multiple myeloma.
Ludwig H; Pohl G; Osterborg A
Clin Adv Hematol Oncol; 2004 Apr; 2(4):233-41. PubMed ID: 16163188
[TBL] [Abstract][Full Text] [Related]
9. Anemia associated with impaired erythropoietin secretion after allogeneic stem cell transplantation: incidence, risk factors, and response to treatment.
Gaya A; Urbano-Ispizua A; Fernández-Avilés F; Salamero O; Roncero JM; Rovira M; Martínez C; Talarn C; Granell M; Carreras E; Montserrat E
Biol Blood Marrow Transplant; 2008 Aug; 14(8):880-7. PubMed ID: 18640571
[TBL] [Abstract][Full Text] [Related]
10. Supportive care and use of hematopoietic growth factors in myelodysplastic syndromes.
Hellström-Lindberg E; Malcovati L
Semin Hematol; 2008 Jan; 45(1):14-22. PubMed ID: 18179965
[TBL] [Abstract][Full Text] [Related]
11. 5-azacitidine: An alternative treatment of myelodysplastic syndromes in patient with refractory response to hematopoietic growth factor, a case report and review of literatures.
Suwanawiboon B; Sumida KN
Hawaii Med J; 2004 Jan; 63(1):14-6, 25. PubMed ID: 15011897
[TBL] [Abstract][Full Text] [Related]
12. EPO in combination with G-CSF improves mobilization effectiveness after chemotherapy with ifosfamide, epirubicin and etoposide and reduces costs during mobilization and transplantation of autologous hematopoietic progenitor cells.
Hart C; Grassinger J; Andreesen R; Hennemann B
Bone Marrow Transplant; 2009 Feb; 43(3):197-206. PubMed ID: 18806833
[TBL] [Abstract][Full Text] [Related]
13. Recombinant human erythropoietin in cancer-related anemia: an evidence-based review.
Desai J; Demetri GD
Best Pract Res Clin Haematol; 2005; 18(3):389-406. PubMed ID: 15792913
[TBL] [Abstract][Full Text] [Related]
14. Advances and challenges in infectious diseases supportive care of patients with hematologic malignancies, hematopoietic stem cell transplantation, and severe aplastic anemia.
Walsh TJ
Semin Hematol; 2009 Jul; 46(3):191-7. PubMed ID: 19549573
[TBL] [Abstract][Full Text] [Related]
15. Reduced-intensity conditioning for the treatment of malignant and life-threatening non-malignant disorders.
Slavin S; Aker M; Shapira MY; Resnick I; Bitan M; Or R
Clin Transpl; 2003; ():275-82. PubMed ID: 15387119
[TBL] [Abstract][Full Text] [Related]
16. [Erythropoietin: a study of its use in oncohematology].
Fernández Martín JM; Villa Rubio A; Cameán Fernández M; Borrero Rubio JM; Martínez Díaz C; Díaz Navarro J; Moreno Sánchez FC; Serrano Ruiz FJ
Farm Hosp; 2004; 28(1):20-8. PubMed ID: 15012175
[TBL] [Abstract][Full Text] [Related]
17. Haematopoietic stem cell transplantation: current status.
Kumar L
Natl Med J India; 2007; 20(3):128-37. PubMed ID: 17867617
[TBL] [Abstract][Full Text] [Related]
18. [Current management of myelodysplastic syndromes].
Vey N; Charbonnier A
Rev Prat; 2010 Dec; 60(10):1416-9. PubMed ID: 21425543
[TBL] [Abstract][Full Text] [Related]
19. Stem cell transplantation and hematopoietic growth factors.
Richard S; Schuster MW
Curr Hematol Rep; 2002 Nov; 1(2):103-9. PubMed ID: 12901131
[TBL] [Abstract][Full Text] [Related]
20. Nonmyeloablative stem cell transplantation and cell therapy for malignant and non-malignant diseases.
Resnick IB; Shapira MY; Slavin S
Transpl Immunol; 2005 Aug; 14(3-4):207-19. PubMed ID: 15982565
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
